

TauroPace™

The problem

Rising number of CIED infections

The impact

High mortality rates despite treatment



The solution

TauroPace™ to prevent CIED infection

Infections occur in 1–4 % of all cardiac implantable electronic devices (CIED). [1-3]

22–56 % of patients are at increased risk for CIED infections. [4-5]

Mortality rates increased to 8-15 % after CIED infection despite standard treatment. [3]



26–29 days average length of hospital stay after CIED infection [6]

50 % excess mortality at three years [7]

€59,477 incremental cost to treat a major CIED infection [8]

€10,000 average hospital margin loss per CIED infection [9]



More information

“ *Taurolidine may be one step closer to the ‘Silver Bullet’ that will kill the microbes, prevent CIED infection, and not affect the host.* ”

[10]



The antimicrobial solution to prevent CIED infection



TauroPace™ contains taurolidine, an antimicrobial agent with a broad activity against all relevant pathogens, incl. multi-resistant superbugs.



TauroPace™ does not contain antibiotics, no resistance patterns have been observed.

TauroPace™ is certified for use during the procedure of placing or revising CIEDs with the aim to upgrade, downgrade, or substitute (i.e. during any surgical procedure).


Taurolidine prevents biofilm formation by inhibiting microbial adhesion to surfaces and destroys microbial cell membranes and toxins. [11]

Biofilm eradication with taurolidine

[12]



10 min.



Clinically proven efficacy

	Borov et al. 2023 [12]	Vonthein et al. 2024 [13]
Time period	2017-2022	2020-2022
Number of patients	631	785
Number of procedures	654	822
CIED infection rate 3 months post procedure	0.00 %	0.125 %
Adverse events reported	none	none

1) Polyzos et al. EP Europace 2015. DOI: 10.1093/europace/euv053
 2) Rennert-May et al. Heart Rhythm 2020. DOI: 10.1016/j.hrthm.2020.02.012
 3) Baldauf et al. Scientific Reports 2024. DOI: 10.1038/s41598-024-82622-1
 4) Mittal et al. Heart Rhythm 2014. DOI: 10.1016/j.hrthm.2013.12.013
 5) Eby et al. EP Europace 2018. DOI: 10.1093/europace/euy015.306
 6) Ahmed et al. PLoS One 2019. DOI: 10.1371/journal.pone.0206611
 7) Sohail et al. Pacing Clin Electrophysiol 2015. DOI: 10.1111/pace.12518

8) Ludwig et al. J Comp Eff Res 2018. DOI: 10.2217/ceer-2017-0080
 9) Unpublished WIDO data on file at CAU Medical Faculty (Kiel, Germany).
 10) Love. EP Europace 2023. DOI: 10.1093/europace/ead333
 11) Torres-Viera et al. Antimicrob Agents Chemother 2000. DOI: 10.1128/AAC.44.6.1720-1724.2000
 12) Ocana et al. Poster presented at ESPEN 2024.
 13) Borov et al. EP Europace 2023. DOI: 10.1093/europace/euad306
 14) Vonthein et al. J Cardiothorac Surgery. DOI: 10.1186/s13019-024-03059-1

